Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals

Pharmaceutical Research

Volumn 30, Issue 3, 2013, Pages 655-669

  Krzyzanski, Wojciech ^a   Sutjandra, Liviawati ^b   Perez Ruixo, Juan Jose ^b   Sloey, Bethlyn ^b   Chow, Andrew T ^b   Wang, Yow Ming ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b AMGEN INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

c Mpl receptor; peptibody; pharmacodynamics mediated drug disposition (PDMDD); pharmacokinetic and pharmacodynamic modeling

Indexed keywords

ROMIPLOSTIM;

AGING; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RHESUS MONKEY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BLOOD PLATELETS; MACACA FASCICULARIS; MACACA MULATTA; MODELS, BIOLOGICAL; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 84878133418     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0894-2     Document Type: Article

References (46)

1. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood. 1993;82:1395-401.
2. Sheridan WP, Choi E, Toombs CF, Nichol J, Fanucchi M, Basser RI. Biology of thrombopoiesis and the role of Mpl ligand in the production and function of platelets. Platelets. 1997;8:319-32.
3. Broudyand VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25:52-60.
4. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev. 2002;13:61-73.
5. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599-602.
6. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-8.
7. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628-38.
8. Molineuxand G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 2010;150:9-20.
9. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-81.
10. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345-56.
11. Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN. Investigation of the Pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res. 2011;28:1931-38.
12. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248-52.
13. Sugiyamaand Y, Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res. 1989;6:192-202.
14. Mager and DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507-32.
15. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007;34:849-68.
16. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol. 2006;46:747-57.
17. Jinand F, Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci. 2004;6:E9.
18. Samtani MN, Perez-Ruixo JJ, Brown KH, Cerneus D, Molloy CJ. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. J Clin Pharmacol. 2009;49:336-50.
19. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12:729-40.
20. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63:548-61.
21. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/ pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res. 2006;23:95-103.
22. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50:793-807.
23. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther. 2003;306:262-70.
24. Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004;309:1085-92.
25. Magerand DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22:1589-96.
26. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514-22.
27. Perez-Ruixo JJ, Krzyzanski W, Hing J. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet. 2008;47:399-415.
28. Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn. 2011;38:179-204.
29. Bauer R. NONMEM Users Guide Introduction to NONMEM 7.2.0, ICON Development Solutions Ellicott City, MD, 2011.
30. Yano Y, Beal S, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171-92.
31. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999;105:478-85.
32. Krzyzanski W, Perez Ruixo JJ. Lifespan based indirect response models. J Pharmacokinet Pharmacodyn. 2012;39:109-23.
33. Schremer S. The blood morphology of laboratory animals. Philadelphia: F. A. Davis Company; 1967.
34. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-68.
35. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology. 1996;89:573-8.
36. Waldmannand TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1-110.
37. Ferl GZ, Wu AM, DiStefano 3rd JJ. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33:1640-52.
38. Gargand A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34:687-709.
39. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 12(4):646-57.
40. Hansen and RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003;92:1206-15.
41. Kuterand DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-69.
42. Sato T, Fuse A, Niimi H, Fielder PJ, Avraham H. Binding and regulation of thrombopoietin to human megakaryocytes. Br J Haematol. 1998;100:704-11.
43. Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007;9:E181-9.
44. Corash L, Shafer B, Perlow M. Heterogeneity of human whole blood platelet subpopulations. II. Use of a subhuman primate model to analyze the relationship between density and platelet age. Blood. 1978;52:726-34.
45. Hjortand PF, Paputchis H. Platelet life span in normal, splenectomized and hypersplenic rats. Blood. 1960;15:45-51.
46. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother. 1956;11:379-93.